Responds to global demand for biosafety testing for drug development and commercialization Expansion creates nearly 500 new jobs in Glasgow and Stirling...
This strategic partnership represents a significant milestone in Synexa's commitment to global health security and its dedication to fostering collaboratio...
HMBD-002, a non-depleting, high-affinity anti-VISTA antibody, possesses key design features enabling robust anti-tumor activity in pr...
Merck, a leading science and technology company, today announced that 43 abstracts covering several modalities and mechanisms will be presented at the 2023...
Azenta, Inc. (Nasdaq: AZTA) announced it has been selected by the Lupus Research Alliance and its clinical research affiliate Lupus Therapeutics to s...
The center is outfitted with two automation solutions, each coupled to their own SCIEX Echo® MS system. This combined offering aims to showcase compreh...
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon p...
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that the U.S. Food and Drug Administration (FDA) has cleare...
Agilent respectfully disagrees with the PTAB’s opinion of unpatentability in view of prior art previously considered by the USPTO during its primary ...
Next&Bio has teamed up with the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) to establish ...
GenScript Biotech Corporation, the world's leading provider of life-science research tools and services, has expanded its primary manufacturing facil...
With more than 80% of its rapidly growing revenues tied to large molecule applications, Wyatt accelerates Waters' ability to build a high-growth business i...
10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it has won an injunction in its patent litigation ...
$3,000,000,000 aggregate principal amount of 4.650% Notes due 2025 $3,000,000,000 aggregate principal amount of 4.450% Notes due 2026 $4,000,000,000 aggr...
© 2024 Biopharma Boardroom. All Rights Reserved.
